Patent ID: 8557800

Claim:
A method of inhibiting sphingosine kinase in a patient in need of such inhibition, the method comprising administering to the patient a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: X is —C(R 3 ,R 4 )N(R 5 )— or —C(O)N(R 4 )—; R 1 is phenyl substituted with 1 to 5 groups that are independently halogen, haloalkyl, CONR′R″, —OC(O)NR′R″, —NR′C(O)R″, —CF 3 , —OCF 3 , —CN, —CO 2 H, —S-alkyl, —SOR′R″, SO 2 R′, wherein R′ and R″ are independently H or (C 1 -C 6 )alkyl, and wherein each alkyl portion of a substituent is optionally further substituted with 1, 2, or 3 groups independently selected from halogen, CN, OH, and NH 2 ; R 2 is aryl, -alkyl-aryl, heteroaryl, -alkyl-heteroaryl, heterocycloalkyl or -alkyl-heterocycloalkyl; R 3 is H or -alkyl; wherein the alkyl and ring portion of each of the above R 2 and R 3 groups is optionally substituted with up to 5 groups that are independently (C 1 -C 6 )alkyl, halogen, haloalkyl, —OC(O)(C 1 -C 6 alkyl), —C(O)O(C 1 -C 6 alkyl), —CONR′R″, —OC(O)NR′R″, —NR′C(O)R″, —CF 3 , —OCF 3 , —OH, C 1 -C 6 alkoxy, hydroxyalkyl, —CN, —CO 2 H, —SH, —S-alkyl, —SOR′R″, —SO 2 R′, —NO 2 , or NR′R″, wherein R′ and R″ are independently H or (C 1 -C 6 )alkyl, and wherein each alkyl portion of a substituent is optionally further substituted with 1, 2, or 3 groups independently selected from halogen, CN, OH, and NH 2 ; and R 4 and R 5 are independently H or alkyl.